Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Evas Therapeutics

2003 FOUNDED
PRIVATE STATUS
Grant LATEST DEAL TYPE
$1.69M LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of technologies for debilitating diseases associated with tissue injury and cell death. The company develops technology for molecular imaging and pharmacotherapy of various debilitating diseases including acute myocardial infarction, stroke, unstable atherosclerotic diseases, transplant rejection, hemodialysis vascular access failure and neurodegenerative diseases.

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Devices and Supplies
Other Industries
Biotechnology
Primary Office
  • 613 Huntley Heights Drive
  • Ballwin, MO 63021
  • United States

+1 (636) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Evas Therapeutics’s full profile, request a free trial.

Evas Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant $1.69M Completed Startup
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Evas Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Accelerate St. Louis Accelerator/Incubator 000 0000 000000 0

Evas Therapeutics Executive Team (1)

Name Title Board
Seat
Contact
Info
Tze-Chein Wun Owner